BiotechTube
Apoplex Medical Technologies

Apoplex Medical Technologies

Munich, Germany· Est.
apoplexmedical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.2M

Overview

Apoplex Medical Technologies has developed SRA®, a validated, AI-based software platform for the automated detection of atrial fibrillation (AF) from ECG data, primarily targeting stroke units. The technology claims to double the detection rate of paroxysmal AF in one-third the time of conventional methods, thereby addressing a critical gap in stroke prevention. Trusted by over 200 clinics globally, including 40% of stroke units in Germany, the company offers a 'zero-click' workflow that reduces clinical workload and enables faster, data-driven patient management decisions. Its business model is commercial, generating revenue through the sale of its diagnostic analysis service to hospitals.

CardiovascularNeurology

Technology Platform

SRA® (Stroke Risk Analysis) - An AI-powered, fully automated software platform that analyzes continuous ECG data from patient monitors or Holter recorders to detect paroxysmal atrial fibrillation (AF). It features a 'zero-click' workflow, encrypted data transmission, and generates reports with an AF Risk Score within 24 hours.

Funding History

1
Total raised:$1.2M
Seed$1.2M

Opportunities

Significant opportunity for geographic expansion beyond Germany, particularly into other European markets and North America.
The growing emphasis on AI in healthcare and value-based care models creates a favorable environment for solutions that improve diagnostic efficiency and patient outcomes.
Potential to expand the technology platform to detect other cardiac arrhythmias, broadening its market applicability.

Risk Factors

Faces competition from both large medtech companies integrating AI into monitors and other specialized AI-ECG startups.
Expansion is dependent on navigating diverse and complex regulatory and reimbursement landscapes in new countries.
The business is reliant on the continued clinical validation and superiority of its core algorithm against evolving competitors.

Competitive Landscape

The competitive landscape includes large medical device companies (e.g., Philips, GE Healthcare, Boston Scientific) that offer cardiac monitoring solutions with increasingly sophisticated software analytics. There are also numerous pure-play digital health and AI-ECG analysis startups (e.g., AliveCor, Cardiologs) focusing on arrhythmia detection. Apoplex differentiates through its deep, validated integration into the specific workflow of hospital stroke units and its strong clinical evidence base in that setting.

More companies in AI / Machine Learning →More companies in Germany →